Regeneron Pharmaceuticals insider trading
Every open-market purchase and sale by Regeneron Pharmaceuticals's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Regeneron Pharmaceuticals’s insiders pay?
From May 17, 2010 to November 10, 2025, 27 insiders reported 45 open-market purchases and 182 sales not made under a pre-set plan in Regeneron Pharmaceuticals. Twelve months after each purchase was reported, the shares were +26.2% against the S&P 500 on average (median +31.7%), over 45 purchases with a full year of prices; 78% beat the index. After sales, the shares moved +5.5% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 20, 2010 into $31,831 by November 2, 2026, +7.3% a year. It held shares 35% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $24,726 (+5.7% a year), and held throughout $94,104 (+14.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Sanofi | 10% owner | 40 | +20.1% (40) | 75% | 7 | −14.2% (7) | June 11, 2020 |
| Sing George L | Director | 1 | +73.9% (1) | 100% | 30 | +0.1% (30) | February 28, 2024 |
| Goldstein Joseph L | Director | 0 | — | — | 21 | +24.2% (21) | August 24, 2020 |
| Van Plew Daniel P | EVP & General Mgr, Industrial | 0 | — | — | 21 | +3.9% (21) | February 16, 2024 |
| Stahl Neil | EVP Research and Development | 0 | — | — | 19 | +20.4% (19) | February 8, 2024 |
| Brown Michael S | Director | 0 | — | — | 11 | +19.4% (11) | February 24, 2022 |
| Ryan Arthur F | Director | 1 | +97.8% (1) | 100% | 10 | +18.9% (10) | August 8, 2022 |
| Vagelos P Roy | Chairman of the Board | 0 | — | — | 10 | +7.2% (10) | August 23, 2017 |
| Poon Christine A | Director | 2 | +41.1% (2) | 100% | 7 | −12.9% (6) | October 31, 2025 |
| Tessier-Lavigne Marc | Director | 0 | — | — | 6 | −7.3% (6) | May 8, 2020 |
| Gilman Alfred G | Director | 0 | — | — | 5 | +15.3% (5) | August 7, 2015 |
| Shooter Eric M | Director | 0 | — | — | 5 | +37.3% (5) | February 13, 2014 |
| Larosa Joseph J | EVP General Counsel and Secret | 0 | — | — | 4 | −40.1% (4) | February 28, 2024 |
| Mccorkle Douglas S | VP Controller and Asst Treasur | 0 | — | — | 4 | −3.5% (4) | August 5, 2015 |
| Mccourt Marion | EVP Commercial | 0 | — | — | 4 | −7.8% (4) | February 6, 2024 |
| Terifay Robert J | SVP Commercial | 0 | — | — | 4 | +1.0% (4) | August 7, 2015 |
| Fenimore Christopher R. | SVP Finance & CFO | 0 | — | — | 2 | −60.9% (2) | August 29, 2024 |
| Landry Robert E | EVP Finance CFO | 0 | — | — | 2 | −9.0% (2) | August 25, 2023 |
| Pitofsky Jason | VP Controller | 0 | — | — | 2 | −72.5% (1) | November 10, 2025 |
| Powchik Peter | SVP Clinical Development & Reg | 0 | — | — | 2 | +16.6% (2) | August 17, 2015 |
| Aberman Michael S | VP Strategy and Investor Relat | 0 | — | — | 1 | −11.1% (1) | May 8, 2013 |
| Bassler Bonnie L | Director | 0 | — | — | 1 | −48.3% (1) | February 26, 2024 |
| Ingram Robert Alexander | Director | 0 | — | — | 1 | −23.8% (1) | May 27, 2015 |
| Roberts William | VP Regulat Dev & Med Safety | 0 | — | — | 1 | +23.7% (1) | December 4, 2012 |
| Sanofi-Aventis Amerique Du Nord S.n.c. | 10% owner | 1 | +121.9% (1) | 100% | 0 | — | October 14, 2010 |
| Yancopoulos George | President Regeneron Laboratori | 0 | — | — | 1 | −11.1% (1) | May 8, 2013 |
| Zoghbi Huda Y | Director | 0 | — | — | 1 | −56.6% (1) | May 8, 2020 |
When several insiders traded Regeneron Pharmaceuticals
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Regeneron Pharmaceuticals in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +26.7% against the index. After 17 selling crowds, +13.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 30, 2024 | 3 selling | −43.9% | −46.0% | −68.5% |
| February 29, 2024 | 7 selling | −2.8% | +11.4% | −45.0% |
| August 31, 2023 | 4 selling | −2.0% | +2.9% | +17.1% |
| August 31, 2022 | 3 selling | +25.8% | +30.9% | +27.1% |
| March 31, 2022 | 3 selling | +0.5% | +18.9% | +25.8% |
| August 31, 2021 | 3 selling | −6.7% | −6.0% | −2.5% |
| February 28, 2020 | 3 selling | +34.5% | +19.5% | −29.8% |
| November 29, 2019 | 3 selling | +29.1% | +68.3% | +22.4% |
| May 31, 2019 | 3 selling | −10.5% | +7.5% | +85.4% |
| June 29, 2018 | 3 selling | +9.5% | +15.2% | −20.0% |
| August 29, 2014 | 5 selling | +15.0% | +11.4% | +46.1% |
| May 30, 2014 | 2 buying | +8.6% | +26.7% | +55.4% |